Is there a standard induction regimen for patients with AML?
Mené sur 620 patients atteints d'une leucémie myéloïde aiguë avant 60 ans, cet essai chinois de phase III évalue l'efficacité et la toxicité d'un traitement d'induction à base d'homoharringtonine, un alcaloïde extrait d'un conifère originaire des provinces du Sud de la Chine
In the Lancet Oncology , Jie Jin and colleagues report results of a randomised study investigating the addition of homoharringtonine to induction treatment of patients younger than 60 years with acute myeloid leukaemia. Homoharringtonine is a natural plant alkaloid derived from Cephalotaxus species and has been assessed by Chinese investigators for treatment of myeloid neoplasms. A semisynthetic version—omacetaxine mepesuccinate—is a highly purified form that has been approved by the US Food and Dru ...
The Lancet Oncology , commentaire, 2012